ArticleInternational journal of biological sciences2026
FKBP9 Drives Hepatocellular Carcinoma EMT by Regulating SEPT6 Transcription and Stability to Activate TGF-β Signaling.
Article in International journal of biological sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Epithelial-mesenchymal transition (EMT) drives hepatocellular carcinoma (HCC) progression, yet key EMT-driving genes specifically acting in malignant epithelial subpopulations remain poorly characterized. Here, we systematically screened EMT-related genes with cancer cell-specific high expression in HCC, and investigated the functional roles and downstream mechanisms of FKBP9. We found that FKBP9 was specifically highly expressed in HCC cancer cell subpopulations, and functionally promoted HCC cell proliferation, clonogenicity, migration and EMT progression. Mechanistically, FKBP9 enhanced SEPT6 transcription by upregulating c-MYC, and directly bound to SEPT6 protein to increase its stability, which in turn activated the TGF-β1 signaling cascade to drive EMT. We further validated the preclinical anti-HCC efficacy of pinyonomycin as a putative FKBP9-targeting inhibitor. Our findings indicate that FKBP9 drives HCC progression and EMT via the SEPT6-mediated TGF-β pathway, highlighting FKBP9 as a promising therapeutic target for HCC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.